Differential effects of dopamine D-1 and D-2 agonists and antagonists in 6-hydroxydopamine-lesioned rats.
Arnt
J
J
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects*; D004873:Ergolines / Q000494:pharmacology; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology*; D016627:Oxidopamine; D010479:Pergolide; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013239:Stereotyped Behavior / Q000187:drug effects*
D001552:Benzazepines; D004873:Ergolines; D006892:Hydroxydopamines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D010479:Pergolide; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine; D000661:Amphetamine